What is the therapeutic effect of Platinib Hydrochloride Capsules on pancreatic cancer?

Platinib hydrochloride capsule, as the first potent, oral, selective RET inhibitor launched in China, has a significant inhibitory effect on RET fusions and mutations, regardless of tumor type. In recent years, the drug's therapeutic effect in non-small cell lung cancer (NSCLC) and thyroid cancer (TC) has attracted much attention.

In multiple clinical studies, platinib has demonstrated significant efficacy against pancreatic cancer. For example, in the ARROW study, pancreatic cancer patients treated with platinib experienced significant tumor shrinkage. Specifically, the study included multiple patients with RET-positive advanced solid tumors, including patients with pancreatic cancer. Among these patients, tumor shrinkage was observed in 91% of patients, which is much higher than the efficacy of traditional chemotherapy or radiation therapy. More importantly, 1 pancreatic cancer patient achieved complete response (CR), that is, the tumor completely disappeared, which is a very rare and encouraging result.

In addition to tumor shrinkage, platinib also demonstrated a high objective response rate (ORR) in patients with pancreatic cancer. In the ARROW study, the ORR in patients with pancreatic cancer reached an astonishing 100%, meaning that all patients who received treatment experienced a response. In addition, the median progression-free survival (PFS) and overall survival (OS) also reached 7 months and 14 months respectively, which are considerable results for patients with advanced pancreatic cancer. These data fully demonstrate the excellent performance of platinib in the treatment of pancreatic cancer.

When evaluating the therapeutic effect of a drug, in addition to its efficacy, its safety and tolerability also need to be considered. Platinib also excels in this regard. In multiple clinical studies, the drug was well tolerated by patients, and adverse reactions were mostly mild and controllable. This means patients can maintain a better quality of life while receiving platinib, while reducing the risk of discontinuation due to side effects of the drug.